全文获取类型
收费全文 | 28520篇 |
免费 | 1804篇 |
国内免费 | 113篇 |
专业分类
耳鼻咽喉 | 405篇 |
儿科学 | 796篇 |
妇产科学 | 561篇 |
基础医学 | 4253篇 |
口腔科学 | 726篇 |
临床医学 | 2765篇 |
内科学 | 5516篇 |
皮肤病学 | 557篇 |
神经病学 | 2615篇 |
特种医学 | 1316篇 |
外国民族医学 | 2篇 |
外科学 | 4225篇 |
综合类 | 252篇 |
一般理论 | 52篇 |
预防医学 | 2034篇 |
眼科学 | 591篇 |
药学 | 1919篇 |
中国医学 | 34篇 |
肿瘤学 | 1818篇 |
出版年
2023年 | 117篇 |
2022年 | 208篇 |
2021年 | 488篇 |
2020年 | 273篇 |
2019年 | 452篇 |
2018年 | 571篇 |
2017年 | 422篇 |
2016年 | 542篇 |
2015年 | 630篇 |
2014年 | 835篇 |
2013年 | 1237篇 |
2012年 | 1672篇 |
2011年 | 1835篇 |
2010年 | 1069篇 |
2009年 | 1007篇 |
2008年 | 1596篇 |
2007年 | 1704篇 |
2006年 | 1702篇 |
2005年 | 1672篇 |
2004年 | 1660篇 |
2003年 | 1543篇 |
2002年 | 1507篇 |
2001年 | 370篇 |
2000年 | 304篇 |
1999年 | 319篇 |
1998年 | 414篇 |
1997年 | 311篇 |
1996年 | 259篇 |
1995年 | 242篇 |
1994年 | 234篇 |
1993年 | 190篇 |
1992年 | 190篇 |
1991年 | 171篇 |
1990年 | 143篇 |
1989年 | 165篇 |
1988年 | 147篇 |
1987年 | 162篇 |
1986年 | 132篇 |
1985年 | 155篇 |
1984年 | 161篇 |
1983年 | 144篇 |
1982年 | 195篇 |
1981年 | 153篇 |
1980年 | 168篇 |
1979年 | 116篇 |
1978年 | 128篇 |
1977年 | 109篇 |
1976年 | 111篇 |
1974年 | 92篇 |
1973年 | 78篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
41.
Kathryn K Bucci Carl J Possidente Kathleen A Talbot 《American journal of health-system pharmacy》2003,60(24):2601-2605
42.
An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies. 总被引:3,自引:0,他引:3
Joachim Wernicke Alberto Lledó Joel Raskin Daniel K Kajdasz Fujun Wang 《Drug safety》2007,30(5):437-455
BACKGROUND AND OBJECTIVE: In recent years, new classes of medication, such as the serotonin-noradrenaline reuptake inhibitors (SNRIs), have been developed for use in the treatment of major depressive disorder (MDD). For many years, treatment options were largely limited to the use of monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs) and selective serotonin reuptake inhibitors (SSRIs). However, there have been published reports of orthostatic hypotension, arrhythmias and corrected QT (QTc) interval changes in patients treated with TCAs. As new medications become available, it is important to understand how their cardiovascular safety profile compares with that of more established agents to aid clinicians and patients in choosing the best treatment options. This study was designed to evaluate the cardiovascular safety profile of the SNRI duloxetine through evaluation of cardiovascular-related parameters and adverse events (AEs). METHODS: The cardiovascular safety of duloxetine was assessed using all placebo-controlled duloxetine clinical trial data as of December 2005. This consisted of data from 42 placebo-controlled clinical trials of 8504 patients who were treated with duloxetine. Additional information from a high-dose clinical pharmacology study and postmarketing safety surveillance are also presented. Of the placebo-controlled trials included in this analysis, clinical indications under investigation included MDD (15 studies), diabetic peripheral neuropathic pain (3 studies), fibromyalgia (2 studies), generalised anxiety disorder (3 studies) and lower urinary tract disorders (19 studies, all related to incontinence). Cardiovascular safety was evaluated based on vital signs, ECGs and the incidence of treatment-emergent AEs potentially related to cardiovascular safety. These safety parameters were analysed across all indications. To identify both serious and non-serious cardiovascular-related AEs, as well as AEs reported as the reason for discontinuation, a comprehensive list of terms derived from the Medical Dictionary for Regulatory Activities (version 8.0) was generated and used to search the duloxetine databases for cardiovascular-related events. RESULTS: Calculation of change from baseline to maximum in ECG parameters showed significant differences between treatment groups for all parameters, with decreases from baseline in RR, QRS and QT intervals for patients receiving duloxetine and increases from baseline for patients treated with placebo. These shifts were related to small heart rate changes, but the mean differences were not considered clinically relevant. Categorical analyses of shifts from normal to abnormal (or abnormal to normal) for heart rate and QT corrected for heart rate using Fridericia's formula (QTcF) values showed that most patients did not shift from their baseline category. Patients with MDD who were treated for up to 1 year with duloxetine had blood pressure changes early in treatment that then stabilised. Even in patients with elevated blood pressure at baseline in these clinical trials, no increased risk of sustained blood pressure elevation with duloxetine treatment was found. CONCLUSION: Overall, the findings presented here support our conclusions that use of duloxetine does not appear to be associated with significant cardiovascular risks in patients with conditions for which the drug has been approved or studied. 相似文献
43.
Carl L. Nelson Sandra G. Hickmon Robert A. Skinner 《Journal of orthopaedic research》1997,15(2):249-255
Osteomyelitis was induced in the radius in 77 rabbits and confirmed by histological examination and culture. At 4 weeks, the wounds were debrided and the animals were treated with (a) fatty acid dimersebacic acid beads (a bioerodable composite) impregnated with 20% or (b) 10% gentamicin sulfate, (c) placebo beads and intramuscular gentamicin sulfate. (d) placebo beads alone, or (e) debridement only. After 4 weeks, eradication of infection was determined by histological examination and culture. Osteomyelitis was eradicated in 93% of the animals treated with the beads and 20% gentamicin, in 67% of those treated with the beads arid 10% gentamicin, in 25% of those treated with placebo beads and intramuscular gentamicin, in 7% of those treated with placebo beads alone, and in 12.5% of those treated with debridement only (p values from <0.001 to 0.02). Fatty acid dimer-sehacie acid beads with gentamicin were then implanted in noninfected rabbits, and gentamicin sulfate concentrations in bone, serum, urine, and wound exudate were measured. Gentamicin sulfate was detectable in bone for as long as 8 weeks after implantation. Levels as high as 4,746 g/ml were present in the wound exudate for the first 7 days. Levels in the serum peaked at 1.03 μg/ml. Urine levels peaked at 135 μg/ml. 相似文献
44.
45.
Role of substance P in several models of bladder inflammation 总被引:1,自引:0,他引:1
Judith Luber-Narod Tammy Austin-Ritchie Carl Hollins III Mani Menon Rajwant K. Malhotra Stephen Baker Robert E. Carraway 《Urological research》1997,25(6):395-399
Substance P (SP) is a peptide found in the sensory nervous system which has multiple biologic effects including stimulation of muscle contraction, pain nociception, immune cell functions, plasma extravasation and a constellation of inflammatory effects. Here we investigate the role of SP in several animals models of bladder inflammation. Using the female Lewis rat, inflammation was induced using either xylene, lipopolysaccharide (LPS) or polyinosinic-polycytidylic acid (polyIC). Inflammation occurred rapidly (4 h) and was maintained in each model for at least 7 days. Each of these protocols decreased the bladder content of immunoreactive SP by approximately 50%, suggesting enhanced release. There was no change in the urinary frequency of these animals over 3 weeks, suggesting that urinary frequency changes are not mediated by acute inflammation. We also found that the SP receptor (NK1) antagonist, (?)CP96345, was unable to block the inflammation produced by polyIC, suggesting that SP is not an obligatory mediator of immune cell stimulation in this model. 相似文献
46.
47.
Jesper Carl Thomas Bro Christensen Hans von der Maase 《Acta oncologica (Stockholm, Sweden)》1992,31(7):749-753
This study presents an analysis on longitudinal tumour marker series in twenty-two patients with non-seminomatous germ cell cancers treated with cisplatinum (DDP) based combination chemotherapy. Series of alphafoetoprotein (AFP), human chorionic gonadotropin (HCG) and lactate dehydrogenase (LDH) were analyzed applying a dynamic mathematical marker model. The model analysis provided quantitated values for growth rate and treatment response in the marker producing cells. The analysis showed that LDH had to be above 2 000 U/l to be a trustworthy tumour marker. HCG producing cells tended to grow faster than AFP producing cells, and were 3-5-fold more sensitive to the chemotherapy given than AFP producing cells. Treatment response versus DDP dose appeared to be bi-phasic, but with no significant change in treatment efficiency within the given range of DDP doses. 相似文献
48.
Markus Kohlhaas Olaf Stahlhut Joachim Tholuck Gisbert Richard 《Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft》1997,94(7):515-518
Ziel der vorliegenden Untersuchung war es, das Ausma? der Hornhautsch?digung durch eine Kataraktextraktion im Hinblick auf
das Hornhautendothel und die Hornhautdicke zu untersuchen.
Patienten und Methode: In einer prospektiven Untersuchung wurde die Entwicklung der Hornhautdicke und der Endothelzelldichte
an 48 Patienten untersucht. Die Patienten wurden mittels Phakoemulsifikation operiert. Die Hornhautdicke wurde dabei mit einem
Ultraschallpachymeter bei 12 Uhr und im Hornhautzentrum und die Endothelzelldichte mit einer Endothelzellkamera an den gleichen
Me?punkten pr?operativ sowie 4 Wochen, 4 Monate und 1 Jahr postoperativ bestimmt.
Ergebnisse: Ein Jahr postoperativ nahm die Hornhautdicke nach Phakoemulsifikation an der 12-Uhr-Position um ca. 9% und im
Hornhautzentrum um ca. 12% im Vergleich zum pr?operativen Wert zu. Die Endothelzelldichte war 1 Jahr postoperativ an der 12-Uhr-Position
um ca. 27% und im Zentrum um ca. 18% reduziert. Das Patientenalter korrelierte signifikant mit dem Zellverlust an beiden Me?punkten.
Bezüglich der Dickenzunahme ist keine signifikante Korrelation festzustellen.
Schlu?folgerung: Nach einer Kataraktextraktion ist der Hornhautstoffwechsel reduziert. Als Indikator k?nnen der Verlauf der
Endothelzelldichte und der Dicke herangezogen werden.
相似文献
49.
50.
Mark F. Cotton Peter R. Donald Johan F. Schoeman Lana E. Van Zyl Cor Aalbers Carl J. Lombard 《Child's nervous system》1993,9(1):10-15
Intracranial pressure (ICP) monitored shortly after admission over a period of 1 h in 31 children with tuberculous meningitis (TBM) was significantly higher (median 22.5 mm Hg, range 8.4–50.9 mmHg) in 19 children with laboratory evidence of the syndrome of inappropriate antidiuretic hormone secretion (SIADH) than in 12 children without such evidence (median 16.2 mmHg, range 5.8–42.5 mmHg; P = 0.027). Neither plasma nor cerebrospinal fluid arginine vasopressin (AVP) was related to ICP (r = 0.33 and 0.13 respectively). Mean arterial pressure (MAP) was measured in 23 children and a moderate correlation was found with plasma AVP (r = 0.62; P = 0.0019). In TBM, plasma AVP may be secreted as a response to raised ICP in an effort to raise MAP and maintain cerebral perfusion pressure. In this setting excess fluid may be inappropriately retained, leading to hyponatremia and hypo-osmolemia. 相似文献